NOBIVAC BB/PI

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Ingredjent attiv:

BORDETELLA BRONCHISEPTICA; CANINE PARAINFLUENZA VIRUS; ALUMINIUM HYDROXIDE

Disponibbli minn:

INTERVET AUSTRALIA PTY LIMITED

INN (Isem Internazzjonali):

vaccine - canine Bordetella(0.05ug/dose)+vaccine - canine parainfluen

Għamla farmaċewtika:

MISC. VACCINES OR ANTI SERA

Kompożizzjoni:

BORDETELLA BRONCHISEPTICA VACCINE-MICROBIAL Active 0.05 ug/ml; CANINE PARAINFLUENZA VIRUS VACCINE-VIRAL Active 1000000.0 TCI50/ml; ALUMINIUM HYDROXIDE MINERAL-ALUMINIUM-BASE Other 3.0 mg/ml

Unitajiet fil-pakkett:

1 x dose; 10 x dose; 20 x dose; 25 x dose; 5 x dose; 50 x dose

Klassi:

VM - Veterinary Medicine

Manifatturat minn:

INTERVET AUSTRALIA

Grupp terapewtiku:

DOG | BITCH | CASTRATE | PUPPY

Żona terapewtika:

IMMUNOTHERAPY

Indikazzjonijiet terapewtiċi:

BORDETELLA BRONCHISEPTICA | CANINE PARAINFLUENZA | CANINE COUGH SYNDROME | INFECTIOUS TRACHEOBRONCHITIS

Sommarju tal-prodott:

Poison schedule: 0; Withholding period: WHP: N/A; Host/pest details: DOG: [BORDETELLA BRONCHISEPTICA, CANINE PARAINFLUENZA]; For the active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus.AVOID USING in dogs receiving corticosteroids or in pregnant bitches. Refer also to Side Effects, etc. on label.

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2023-07-01

Fuljett ta 'informazzjoni

For Official Use Only
E-LABEL APPLICATION (DRAFT)
COMPANY NAME:
INTERVET AUSTRALIA PTY LIMITED
PRODUCT NAME:
NOBIVAC BB/PI
ELABEL APPLICATION NO:
DC12-62888537E9
APVMA APPROVAL NO:
62433/100831
PRODUCT NO:
62433
VERSION NO:
3.0
APPLICATION STARTED:
2014-Oct-30 11:28:35
VERSION CREATED:
2015-Feb-27 10:40:22
STARTED BY:
Lyn Lavidis
PRINTED:
2015-Feb-27 14:24:09
LABEL NAME:
NOBIVAC BB/PI
SIGNAL HEADINGS:
FOR ANIMAL TREATMENT ONLY
CONSTITUENT
STATEMENTS:
ACTIVE CONSTITUENTS:
Each single dose contains at least: 0.05 µg purified inactivated
Bordetella bronchiseptica
antigen10^6 TCID50 inactivated canine parainfluenza virus and 3 mg
aluminium hydroxide
(adjuvant).
CLAIMS:
INJECTABLE BIVALENT INACTIVATED VACCINE FOR DOGS
For the active immunisation of dogs against Bordetella bronchiseptica
and canine
parainfluenza virus.
NET CONTENTS:
single dose vial
10 x single dose vials
20 x single dose vials
25 x single dose vials
5 x single dose vials
50 x single dose vials
DIRECTIONS FOR USE:
DIRECTIONS FOR USE:
Only healthy dogs possessing normal temperatures should be vaccinated.
CONTRAINDICATIONS:
CONTRAINDICATIONS:
This product should not be used in dogs receiving corticosteroids or
in pregnant bitches.
SIDE EFFECTS:
SIDE EFFECTS
A local reaction may occur at the inoculation sites in some dogs.
DOSAGE AND
ADMINISTRATION:
DOSAGE AND ADMINISTRATION:
Note: The removable label should only be removed after the dose has
been given. RLP APPROVED
For Official Use Only
Under normal circumstances:
Primary vaccination:
Inject subcutaneously or intramuscularly 2 doses of vaccine at an
interval of 1 month to
dogs 6 weeks of age or over. Nobivac® Bb/Pi is suitable for use as a
diluent with Nobivac®
DHP. An annual booster is recommended.
GENERAL DIRECTIONS:
Due to the interference of maternal antibodies with active
immunisation, protection of young
puppies can be difficult, especially in infected kennels.
Epidemiological conditions and the
likely persistence of maternal antibodies (e.g. antibody titres of the
mother, age of weaning)
can t

Karatteristiċi tal-prodott

PRODUCT NAME: NOBIVAC BB/PI
MATERIAL SAFETY DATA SHEET
THIS REVISION ISSUED: JANUARY, 2010
PAGE: 1 OF 5
MATERIAL SAFETY DATA SHEET
Issued by: Intervet Australia Pty Limited Phone: [phone]
(Business Hours)
Poisons Information Centre: 13 11 26 from anywhere in Australia, (0800
764 766 in New Zealand)
CHEMICAL NATURE:
Suspension of inactivated viruses in saline.
TRADE NAME:
NOBIVAC BB/PI
RECOMMENDED USE:
For protection against Bordetella bronchiseptica and canine
parainfluenza in dogs.
APVMA NO:
62433
CREATION DATE:
January, 2010
THIS VERSION ISSUED:
January, 2010
and is valid for 5 years from this date.
STATEMENT OF HAZARDOUS NATURE:
THIS PRODUCT IS CLASSIFIED AS:
Not classified as hazardous according to the criteria of SWA.
Not a Dangerous Good according to the Australian Dangerous Goods (ADG)
Code.
RISK PHRASES:
Not Hazardous - No criteria found.
SAFETY PHRASES:
S23, S25. Do not breathe mists. Avoid contact with eyes.
SUSDP CLASSIFICATION:
None allocated.
ADG CLASSIFICATION:
None allocated. Not a Dangerous Good under the ADG Code.
UN NUMBER:
None allocated
PHYSICAL DESCRIPTION & COLOUR:
White or off-white suspension.
ODOUR:
No data; expected to be almost odourless.
MAJOR HEALTH HAZARDS:
no significant risk factors have been found for this product.
INHALATION:
SHORT TERM EXPOSURE:
Available data indicates that this product is not harmful. In addition
product is unlikely to
cause any discomfort or irritation.
LONG TERM EXPOSURE:
No data for health effects associated with long term inhalation.
SKIN CONTACT:
SHORT TERM EXPOSURE:
Available data indicates that this product is not harmful. It should
present no hazards in
normal use. In addition product is unlikely to cause any discomfort in
normal use.
LONG TERM EXPOSURE:
No data for health effects associated with long term skin exposure.
EYE CONTACT:
SHORT TERM EXPOSURE
: This product may be mildly irritating to eyes, but is unlikely to
cause anything more than mild
discomfort which should disappear once product is removed.
LONG TERM EXPOSURE
: No data for health